Paradigm Biopharmaceuticals (ASX:PAR) Advances Its Pivotal Osteoarthritis Programme

Aditi Sarkar

10 September 2026 10:35 PM AEST

Paradigm Biopharmaceuticals (ASX:PAR) Advances Its Pivotal Osteoarthritis Programme

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Paradigm Biopharmaceuticals (ASX:PAR) is approaching an important stage in its pivotal knee osteoarthritis programme. The clinical-stage company has completed enrolment for its Phase 3 study of injectable pentosan polysulfate sodium, shifting the programme towards safety review and top-line results.

Latest Developments

Paradigm confirmed it completed enrolment in its pivotal Phase 3 knee osteoarthritis study, PARA_OA_012, ahead of schedule. According to company disclosures, the randomised, double-blind, placebo-controlled trial recruited 538 participants across roughly 65 clinical sites in Australia, the United States, Hong Kong and Moldova, exceeding the original target of 466 patients.

Following database lock and data preparation in August 2026, an independent Data Safety Monitoring Board review is targeted for September 2026. A preliminary safety review of approximately 20% of participants reported no material safety concerns. Top-line primary-endpoint results are anticipated in the first quarter of 2027. Reaching this stage marks the culmination of a multi-year clinical effort and shifts the market's attention firmly toward the read-out timeline.

What Could Come Next

The nearest signpost is the outcome of the DSMB review. Beyond that, the primary-endpoint data expected in early 2027 will be decisive for the programme and for any future regulatory pathway with agencies such as the US FDA. Positive data could support partnering or licensing discussions, while additional funding decisions may follow depending on results and cash needs. The company had previously indicated it would advance the knee osteoarthritis programme to Phase 3 following US FDA review, so regulatory engagement will remain a focus alongside the clinical data.

Risks to Watch

Drug development is inherently high-risk. Phase 3 trials can miss their primary endpoint even after encouraging earlier-stage data, and safety signals can emerge at any point. As a pre-profit company, Paradigm may need further capital, which could dilute existing holders.

Conclusion

Paradigm has completed enrolment and moved its pivotal osteoarthritis study towards safety review and the planned early-2027 read-out. Clinical outcomes, regulatory engagement and future funding will determine the programme's next stage.

FAQs

Q: What defines the current strategy of Paradigm Biopharmaceuticals Ltd (ASX:PAR)?

A: Paradigm Biopharmaceuticals (ASX:PAR) is approaching an important stage in its pivotal knee osteoarthritis programme. The clinical-stage company has completed enrolment for its Phase 3 study of injectable pentosan polysulfate sodium, shifting the programme towards safety review and top-line results.

Q: What could come next for Paradigm Biopharmaceuticals Ltd (ASX:PAR)?

A: The nearest signpost is the outcome of the DSMB review. Beyond that, the primary-endpoint data expected in early 2027 will be decisive for the programme and for any future regulatory pathway with agencies such as the US FDA.

Q: What are the key risks for Paradigm Biopharmaceuticals Ltd (ASX:PAR)?

A: Drug development is inherently high-risk. Phase 3 trials can miss their primary endpoint even after encouraging earlier-stage data, and safety signals can emerge at any point.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.